Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2017

Open Access 01-12-2017 | Review

Intestinal Behçet and Crohn’s disease: two sides of the same coin

Authors: Simona Valenti, Romina Gallizzi, Dominique De Vivo, Claudio Romano

Published in: Pediatric Rheumatology | Issue 1/2017

Login to get access

Abstract

Behçet’s disease (BD) and Crohn’s disease (CD) are chronic immune-mediated, inflammatory disorders affecting many different systems (joints, skin, eyes, gastrointestinal and biliary tracts). Both disorders have fluctuating courses and when gastrointestinal symptoms are prevalent, differential diagnosis can be difficult. BD involves the gastrointestinal tract in 10–15% of cases with localized lesions in the ileocecal region. The clinical picture is heterogeneous with various clusters of disease expression. CD is a chronic inflammatory disorder, which can affect any part of the intestinal tract, as well as extra-intestinal tissue. Factors that contribute towards the pathogenesis of both disease include the host’s genetic profile, and immune system, and environmental factors such as the gut microbiota. The aim of this manuscript is to provide a narrative review of clinical features of BD and CD, highlighting the importance of differential diagnosis and therapeutic approach, especially in the presence of gastrointestinal involvement. A comprehensive search of published literature using the Pubmed (http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​) database was carried out to identify all articles published in English from 1999 to October 2016, using 4 key terms: “Behçet Disease”, “Intestinal Behçet’s Disease”, “Crohn’s Disease” and” Inflammatory Bowel Disease”.
Literature
1.
2.
Behçet H. Rezidivierende aphthose, durch ein virus verusachte geschwure am auge und an den genitalien. Dermatol Wochenschr. 1937;105:1152–7.
3.
Ciccarelli F, De Martinis M, Ginaldi L. An update on autoinflammatory diseases. Curr Med Chem. 2014;21(3):261–9.CrossRefPubMed
4.
5.
Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behçet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492–9.CrossRefPubMed
6.
Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95(16):e3348. doi:10.​1097/​MD.​0000000000003348​.CrossRef
7.
Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behcet’s disease. J Clin Gastroenterol. 2000;30:144–54.CrossRefPubMed
8.
9.
10.
11.
12.
13.
Kim DH, Cheon JH. Intestinal Behçet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J. 2016;57(1):22–32.CrossRefPubMed
14.
15.
Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behçet disease. Gastroenterol Hepatol (N Y). 2012;8(2):103–12.
16.
17.
Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42:703–6.CrossRefPubMed
18.
Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42:698–702.CrossRefPubMedPubMedCentral
19.
Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–25.CrossRefPubMedPubMedCentral
20.
21.
22.
23.
Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239–54. doi:10.​1093/​ecco-jcc/​jjv213. Epub 2015 Nov 27.CrossRefPubMed
24.
Fatemi A, Shahram F, Akhlaghi M, et al. Prospective study of articular manifestations in Behcet’s disease: five-year report. Int J Rheum Dis. 2015;25. doi: 10.​1111/​1756-185X.​12633.
25.
Cheon JH, Celik AF, Kim WH. Behçet’s disease: gastrointestinal involvement. In: Yazici Y, Yazici H, editors. Behçet’s Syndrome. 1st ed. New York: Springer; 2010. p. 165–88.CrossRef
26.
Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18:509–23.CrossRefPubMed
27.
Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–22.CrossRefPubMed
28.
Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:496–505.CrossRefPubMed
29.
30.
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.
31.
32.
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. Gastroenterology. 1976;70:439–44.PubMed
33.
Cheon JH, Han DS, Park JY, Korean IBD Study Group, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet’s disease. Inflamm Bowel Dis. 2011;17:605–13.CrossRefPubMed
34.
Lee HJ, Kim YN, Jang HW, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet’s disease. World J Gastroenterol. 2012;18:5771–8.CrossRefPubMedPubMedCentral
35.
Choi CH, Kim TI, Kim BC, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Behçet’s disease patients: relation to clinical course. Dis Colon Rectum. 2006;49:1849–59.CrossRefPubMed
36.
Shin SJ, Kim BC, Kim TI, et al. Anti-alpha-enolase antibody as a serologic marker and its correlation with disease severity in intestinal Behçet’s disease. Dig Dis Sci. 2011;56:812–8.CrossRefPubMed
37.
Lee KH, Chung HS, Kim HS, et al. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet’s disease. Arthritis Rheum. 2003;48:2025–35.CrossRefPubMed
38.
Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. Br Med J. 1988;297:1105–6.CrossRef
39.
Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–9.CrossRefPubMed
40.
41.
Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730–4.CrossRefPubMed
42.
Kim DH, Chan HC, Lung PFC, et al. Ileocolonoscopy in Crohn’s disease. In: Kim WH, Cheon JH, editor. Atlas of inflammatory bowel diseases. 1st ed. New York: Springer Berlin Heidelberg; 2015. p. 31–51.
43.
Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behçet’s disease. Inflamm Bowel Dis. 2001;7:243–9.CrossRefPubMed
44.
Lee SK, Kim BK, Kim TI, et al. Differential diagnosis of intestinal Behçet’s disease and Crohn’s disease by colonoscopic findings. Endoscopy. 2009;41:9–16.CrossRefPubMed
45.
46.
Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2012;18:750–7.CrossRefPubMed
47.
Hassard PV, Binder SW, Nelson V, et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report. Gastroenterology. 2001;120:995–9.CrossRefPubMed
48.
Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicentre retrospective study. Inflamm Bowel Dis. 2013;19:1833–8.PubMed
49.
Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol. 2014;49:156–62.CrossRefPubMed
50.
De Cassan C, De Vroey B, Dussault C, et al. Successful treatment with adalimumab in a familial case of gastrointestinal Behçet’s disease. J Crohns Colitis. 2011;5:364–8.CrossRefPubMed
51.
Vitale A, Rigante D, Lopalco G, et al. Interleukin-1 Inhibition in Behçet’s disease. Isr Med Assoc J. 2016;18(3–4):171–6.PubMed
52.
Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. doi: http://​dx.​doi.​org/​10.​1016/​j.​crohns.​2014.​04.​005 1179–1207 First published online: 1 October 2014.
53.
Moja L, Danese S, Fiorino G, et al. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease. Aliment Pharmacol Ther. 2015;41(11):1055–65. doi:10.​1111/​apt.​13190. Epub 2015 Apr 13.CrossRefPubMed
54.
Gomollón F, Dignass A, Annese V et al., 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2016:1–23. doi:10.​1093/​ecco-jcc/​jjw168 Ecco Guideline/Consensus Paper.
55.
Jung YS, Cheon JH, Park SJ, et al. Longterm clinical outcomes of Crohn’s disease and intestinal Behcet’s disease. Inflamm Bowel Dis. 2013;19:99–105.CrossRefPubMed
56.
Moon CM, Cheon JH, Shin JK, et al. Prediction of free bowel perforation in patients with intestinal Behçet’s disease using clinical and colonoscopic findings. Dig Dis Sci. 2010;55:2904–11.CrossRefPubMed
57.
58.
Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:1594–602.CrossRefPubMed
Metadata
Title
Intestinal Behçet and Crohn’s disease: two sides of the same coin
Authors
Simona Valenti
Romina Gallizzi
Dominique De Vivo
Claudio Romano
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2017
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-017-0162-4

Other articles of this Issue 1/2017

Pediatric Rheumatology 1/2017 Go to the issue

Research article

Assessment of transition readiness in adolescents and young adults with chronic health conditions

Research article

Comics as an educational tool for children with juvenile idiopathic arthritis

Research article

Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

Research article

ASAS definition for sacroiliitis on MRI in SpA: applicable to children?

Research article

Bone metabolism and inflammatory characteristics in 14 cases of chronic nonbacterial osteomyelitis

Review

Mental health care for youth with rheumatologic diseases – bridging the gap